drugset / Trial / NCT01456169

A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone

NCT01456169

Phase 3 Completed 507 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of the fixed dose combinations of azilsartan medoxomil plus chlorthalidone (40/12.5 and 40/25 mg), once daily, in participants with grades 2 or 3 essential hypertension who do not reach target blood pressure following treatment with 40 mg azilsartan medoxomil monotherapy after 4 weeks.

Timeline

Start
2011-10
Primary completion
2012-12
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azilsartan medoxomil Other / unclassified 40 mg Oral
Subject Chlorthalidone Other / unclassified 12.5 mg Oral
Subject Chlorthalidone Other / unclassified 25 mg Oral